Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study

MLA

Catherine Reed, et al. “Representativeness of European Clinical Trial Populations in Mild Alzheimer’s Disease Dementia: A Comparison of 18-Month Outcomes with Real-World Data from the GERAS Observational Study.” Alzheimer’s Research & Therapy, vol. 10, no. 1, Apr. 2018, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s13195-018-0360-4.

APA

Catherine Reed, Mark Belger, Grazia Dell’Agnello, Kristin Kahle-Wrobleski, Gopalan Sethuraman, Ann Hake, Joel Raskin, & David Henley. (2018). Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study. Alzheimer’s Research & Therapy, 10(1), 1–11. https://doi.org/10.1186/s13195-018-0360-4

Chicago

Catherine Reed, Mark Belger, Grazia Dell’Agnello, Kristin Kahle-Wrobleski, Gopalan Sethuraman, Ann Hake, Joel Raskin, and David Henley. 2018. “Representativeness of European Clinical Trial Populations in Mild Alzheimer’s Disease Dementia: A Comparison of 18-Month Outcomes with Real-World Data from the GERAS Observational Study.” Alzheimer’s Research & Therapy 10 (1): 1–11. doi:10.1186/s13195-018-0360-4.